Become a member of our mailing list to get the latest news, articles, and insightful content.
Subscribe to our Newsletter
Thank You for subscribing with us. We sent you an email regarding this.
Subscribe Now!
Santa Monica, CA - BioSig Technologies, Inc. (OTCQB: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it will be presenting at the Q2 2018 Emerging Medical Technologies Spotlight virtual event, hosted by Life Science Intelligence. Streaming will begin at 13:00 ET, 10:00 PT, on Friday, June 29.
Mrs. Natasha Russkina, Vice President for Business Development & Corporate Finance of BioSig Technologies, Inc., will do a presentation on the Companys business development roadmap, the core value proposition and clinical applications of the Companys proprietary PURE EPTM System and benefits it aims to provide to the global and growing market of arrhythmias. Mrs. Russkina will also cover the Companys positioning within the rapidly emerging space of bioelectronic medicine and the potential it holds for addressing unmet clinical needs for the large patient populations worldwide.
Registrations for the event can be made on the Life Science Intelligence website under http://www.lsintel.com/emerging-medical-technology-spotlight.php.